GlassScriptPhysician profile
Howard A Fogel
NPI 1578618906
$2,193.61
in general payments reported to CMS, 2019-2025
16 companies · $402 in 2025
The $402 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $55.38 · 2022: $89.45 · 2023: $1,395 · 2024: $252 · 2025: $402.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,471 · Consulting Fee: $578.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,471.28 |
| Consulting Fee | $577.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $864.95 | 2023-2025 | Minimed 780g |
| Kuros Biosciences USA, INC | $538.89 | 2023 | |
| Lilly USA, LLC | $165.18 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Abbvie INC. | $113.53 | 2024-2025 | |
| Abbott Laboratories | $112.06 | 2024-2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $91.65 | 2021-2025 | Rybelsus, Ozempic |
| Tandem Diabetes Care, INC. | $68.78 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.77 | 2023-2024 | Jardiance |
| Esperion Therapeutics, INC. | $38.65 | 2025 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $22.82 | 2025 | |
| Janssen Pharmaceuticals, INC | $22.43 | 2023 | Xarelto |
| Mannkind Corporation | $21.70 | 2024 | |
| Sequel Med Tech, LLC | $20.31 | 2025 | Twiist |
| Xeris Pharmaceuticals, INC. | $19.97 | 2025 | Gvoke Hypopen |
| Amneal Pharmaceuticals LLC | $16.81 | 2025 | Unithroid |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cequr Corporation | $15.11 | 2025 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Fogel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.